An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 3, 2014, Pages 253-263

  Bruyère, Olivier ^a   Cooper, Cyrus ^b,c   Pelletier, Jean Pierre ^d   Branco, Jaime ^e   Luisa Brandi, Maria ^f   Guillemin, Francis ^g   Hochberg, Marc C ^h,i,j   Kanis, John A ^k   Kvien, Tore K ^l   Martel Pelletier, Johanne ^d   Rizzoli, René ^m   Silverman, Stuart ^n,o   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITÉ DE LORRAINE   (France)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ Education and Clinical Center   (United States)

^j Veteran Affairs Maryland Health Care System   (United States)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

^l DIAKONHJEMMET HOSPITAL   (Norway)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

^o OMC Clinical Research Center   (United States)

more..

Author keywords

Algorithm; Knee osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CAPSAICIN; CHONDROITIN SULFATE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DULOXETINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROTON PUMP INHIBITOR;

ACUPUNCTURE; ALGORITHM; CONCEPTUAL FRAMEWORK; DRUG INDICATION; DRUG MEGADOSE; EUROPE; HUMAN; KNEE ARTHROPLASTY; KNEE BRACE; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; MANIPULATIVE MEDICINE; PATIENT EDUCATION; PRESCRIPTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR; TREATMENT CONTRAINDICATION; WEIGHT REDUCTION; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; OSTEOARTHRITIS, KNEE;

ALGORITHMS; DISEASE MANAGEMENT; EUROPE; HUMANS; OSTEOARTHRITIS, KNEE;

EID: 84919631358     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.014     Document Type: Review

References (102)

1. Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377:2115-2126.
2. Pereira D., Peleteiro B., Araújo J., Branco J., Santos R.A., Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011, 19:1270-1285.
3. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
4. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012, 64:465-474. [review].
5. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
6. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
7. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
8. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014, 22:363-388.
9. Osteoarthritis: National clinical guidelines for care and management in adults 2008, National Collaborating Centre for Chronic Conditions, Royal College of Physicians, London.
10. National Clinical Guideline Centre. Osteoarthritis: The care and management of osteoarthritis in adults. Clinical guideline CG177; 2014.
11. Bruyère O., Burlet N., Delmas P.D., Rizzoli R., Cooper C., Reginster J.Y. Evaluation of Symptomatic Slow-Acting Drugs in Osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008, 9:165.
12. Hiligsmann M., Cooper C., Arden N., Boers M., Branco J.C., Luisa Brandi M., et al. Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013, 43:303-313.
13. Zhang W., Doherty M., Peat G., Bierma-Zeinstra M.A., Arden N.K., Bresnihan B., et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010, 69:483-489.
14. Fernandes L., Hagen K.B., Bijlsma J.W., Andreassen O., Christensen P., Conaghan P.G., et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013, 72:1125-1135.
15. Christensen R., Bartels E.M., Astrup A., Bliddal H. Effect of weight reduction in obese patients with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007, 66:433-439.
16. Messier S.P., Mihalko S.L., Legault C., Miller G.D., Nicklas B.J., DeVita P., et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. J Am Med Assoc 2013, 310:1263-1273.
17. Anandacoomarasamy A., Leibman S., Smith G., Caterson I., Giuffre B., Fransen M., et al. Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage. Ann Rheum Dis 2012, 71:26-32.
18. Fransen M., McConnell S. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev 2008, 4:CD004376.
19. Bartels E.M., Lund H., Hagen K.B., Dagfinrud H., Christensen R., Danneskiold-Samsøe B. Aquatic exercise for the treatment of knee and hip osteoarthritis. Cochrane Database Syst Rev 2007, 4:CD005523.
20. Kang J.W., Lee M.S., Posadzki P., Ernst E. T'ai chi for the treatment of osteoarthritis: a systematic review and meta-analysis. BMJ Open 2011, 1:e000035. [PubMed PMID: 22021734. Pubmed Central PMCID: PMC3191392. Epub 2011/10/25].
21. Segal N.A. Bracing and orthoses: a review of efficacy and mechanical effects for tibiofemoral osteoarthritis. PM R 2012, 4(Suppl. 5):S89-S96.
22. Raja K., Dewan N. Efficacy of knee braces and foot orthoses in conservative management of knee osteoarthritis: a systematic review. Am J Phys Med Rehabil 2011, 90:247-262.
23. Hunter D., Gross K.D., McCree P., Li L., Hirko K., Harvey W.F. Realignment treatment for medial tibiofemoral osteoarthritis: randomised trial. Ann Rheum Dis 2012, 71:1658-1665.
24. Parkes M.J., Maricar N., Lunt M., LaValley M.P., Jones R.K., Segal N.A., et al. Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis. J Am Med Assoc 2013, 310:722-730.
25. Jones A., Silva P.G., Silva A.C., Colucci M., Tuffanin A., Jardim J.R., et al. Impact of cane use on pain, function, general health and energy expenditure during gait in patients with knee osteoarthritis: a randomised controlled trial. Ann Rheum Dis 2012, 71:172-179.
26. Loyola-Sanchez A., Richardson J., MacIntyre N.J. Efficacy of ultrasound therapy for the management of knee osteoarthritis: a systematic review with meta-analysis. Osteoarthritis Cartilage 2010, 18:1117-1126.
27. Cakir S., Hepguler S., Ozturk C., Korkmaz M., Isleten B., Atamaz F.C. Efficacy of therapeutic ultrasound for the management of knee osteoarthritis: a randomized, controlled, and double-blind study. Am J Phys Med Rehabil 2013, 93:405-412.
28. Corbett M.S., Rice S.J., Madurasinghe V., Slack R., Fayter D.A., Harden M., et al. Acupuncture and other physical treatments for the relief of pain due to osteoarthritis of the knee: network meta-analysis. Osteoarthritis Cartilage 2013, 21:1290-1298.
29. Vickers A.J., Cronin A.M., Maschino A.C., Lewith G., MacPherson H., Foster N.E., et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med 2012, 172:1444-1453.
30. Manheimer E., Cheng K., Linde K., Lao L., Yoo J., Wieland S., et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev 2010, CD001977.
31. Rutjes A.W., Nuesch E., Sterchi R., Kalichman L., Hendriks E., Osiri M., et al. Transcutaneous electrostimulation for osteoarthritis of the knee. Cochrane Database Syst Rev 2009, CD002823.
32. Atamaz F.C., Durmaz B., Baydar M., Demircioglu O.Y., Iyiyapici A., Kuran B., et al. Comparison of the efficacy of transcutaneous electrical nerve stimulation, interferential currents, and shortwave diathermy in knee osteoarthritis: a double-blind, randomized, controlled, multicenter study. Arch Phys Med Rehabil 2012, 93:748-756.
33. Bannuru R.R., Dasi U.R., McAlindon T.E. Reassessing the role of acetaminophen in osteoarthritis: systematic review and meta-analysis. Osteoarthritis Cartilage 2010, 18(Suppl. 2):S250.
34. Herrero-Beaumont G., Ivorra J.A., Del Carmen Trabado M., Blanco F.J., Benito P., Martín-Mola E., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56:555-567.
35. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Robinson V., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2009, CD002946.
36. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
37. Pavelká K., Gatterová J., Olejarová M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
38. Reginster J.Y. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007, 56:2105-2110.
39. Bjordal J.M., Klovning A., Ljunggren A.E., Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007, 11:125-138.
40. Wandel S., Jüni P., Tendal B., Nüesch E., Villiger P.M., Welton N.J., et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010, 341:c4675.
41. Reginster J.Y., Altman R.D., Hochberg M.C. Glucosamine and osteoarthritis. Prescribed regimen is effective. Br Med J 2010, 341:c6335.
42. Groves T. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Report from post publication review meeting. Br Med J 2011, Avilable from: (Published online: http://www.bmj.com/rapid-response/2011/11/03/report-bmj-post-publication-review-meeting).
43. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
44. Altman R.D. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009, 2:359-371.
45. Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008, 24:3029-3035.
46. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
47. Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011, 70:982-989.
48. Reichenbach S., Sterchi R., Scherer M., Trelle S., Burgi E., Burgi U., et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007, 146:580-590.
49. Zegels B., Crozes P., Uebelhart D., Bruyère O., Reginster J.Y. Equivalence of a single dose (1200mg) compared to a three-time a day dose (400mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage 2013, 21:22-27.
50. Martel-Pelletier J., Roubille C., Abram F., Hochberg M.C., Dorais M., Delorme P., et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2013, [Epub ahead of print].
51. Fransen M., Agaliotis M., Nairn L., Votrubec M., Bridgett L., Su S., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014, [Epub ahead of print].
52. Christensen R., Bartels E.M., Astrup A., Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008, 16:399-408.
53. Bartels E.M., Bliddal H., Schondorff P.K., Altman R.D., Zhang W., Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010, 18:289-296.
54. The European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC). Avilable from: 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001985.jsp&mid=WC0b01ac058004d5c1.
55. Reginster J.Y., Badurski J., Bellamy N., Bensen W., Chapurlat R., Chevalier X., et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013, 72:179-186.
56. The European Medicines Agency. European Medicines Agency recommends that Protelos/Osseor remain available, but with further restrictions. Avilable from: 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/02/news_detail_002031.jsp&mid=WC0b01ac058001d126.
57. Lin J., Zhang W., Jones A., Doherty M. Efficacy of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. Br Med J 2004, 329:324-326.
58. Tugwell P.S., Wells G.A., Shainhouse J.Z. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004, 31:2002-2012.
59. Simon L.S., Grierson L.M., Naseer Z., Bookman A.A., Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009, 143:238-245.
60. Chou R., McDonagh M.S., Nakamoto E., Griffin J. Analgesics for osteoarthritis: An update of the 2006 comparative effectiveness review [internet] 2011, Agency for Healthcare Research and Quality (US), Rockville, MD.
61. Underwood M., Ashby D., Cross P., Hennessy E., Letley L., Martin J., et al. TOIB study team. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. Br Med J 2008, 336:138-142.
62. Matthews P., Derry S., Moore R.A., McQuay H.J. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev 2009, 8:CD007403.
63. Zhang W., Jones A., Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004, 63:901-907.
64. Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., et al. Patient preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
65. Lagnaoui R., Baumevielle M., Bégaud B., Pouyanne P., Maurice G., Depont F., et al. Less use of NSAIDs in long-term than in recent chondroitin sulphate users in osteoarthritis: a pharmacy-based observational study in France. Therapie 2006, 61:341-346.
66. Witter J. Celebrex Capsules (Celecoxib) NDA 20-998/S-009 Medical Officer Review. Available from: 2000 [cited 31.03.2011]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf.
67. Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2007, 369:465-473. MEDAL Steering Committee.
68. Bhala N., Emberson J., Merhi A., Abramson S., Arber N., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, 382:769-779. Coxib and traditional NSAID Trialists' (CNT) Collaboration.
69. Latimer N., Lord J., Grant R.L., O'Mahony R., Dickson J., Conaghan P.G., et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. Br Med J 2009, 339:b2538.
70. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-1626.
71. Moore R.A., Derry S., Makinson G.T., McQuay H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005, 7:R644-R655.
72. The European Medicines Agency. Assessment report for non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. EMA/696137/2012; 2012.
73. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 2008, 117:2104-2113.
74. Gislason G.H., Jacobsen S., Rasmussen J.N., Rasmussen S., Buch P., Friberg J., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006, 113:2906-2913.
75. Olsen A.M., Fosbøl E.L., Lindhardsen J., Folke F., Charlot M., Selmer C., et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation 2012, 126:1955-1963.
76. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102. [Erratum in: N Engl J Med 2006;355:221].
77. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
78. US Food and Drug Administration. Information for healthcare professionals: Concomitant use of ibuprofen and aspirin. Available from: 2006. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222.htm.
79. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709-1711.
80. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008, 59:1058-1073. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs, [Erratum in: Arthritis Rheum 2008;58:1686. Dosage error in article text].
81. Bannuru R.R., Natov N.S., Dasi U.R., Schmid C.H., McAlindon T.E. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis-meta-analysis. Osteoarthritis Cartilage 2011, 19:611-619.
82. Rutjes A.W., Jüni P., da Costa B.R., Trelle S., Nüesch E., Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med 2012, 157:180-191.
83. Bannuru R.R., Natov N.S., Obadan I.E., Price L.L., Schmid C.H., McAlindon T.E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009, 61:1704-1711.
84. Abbott T., Altman R.D., Dimef R., Fredericson M., Vad V., Vitanzo P., et al. Do hyaluronic acid injections delay total knee replacement surgery?. Arthritis Rheum 2013, 65:S910-S911.
85. Bannuru R.R., Vaysbrot E.E., Sullivan M.C., McAlindon T.E. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2013, 43:593-599. [pii:S0049-0172(13)00206-0].
86. Bellamy N., Campbell J., Robinson V., Gee T., Bourne R., Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, CD005328. [review].
87. Raynauld J.P., Buckland-Wright C., Ward R., Choquette D., Haraoui B., Martel-Pelletier J., et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003, 48:370-377. [Erratum in: Arthritis Rheum 2003;48:3300].
88. Cepeda M.S., Camargo F., Zea C., Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007, 34:543-555.
89. Emkey R., Rosenthal N., Wu S.C., Jordan D., Kamin M. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004, 31:150-156. CAPSS-114 Study Group.
90. Altman R.D. Pain relief in osteoarthritis: the rationale for combination therapy. J Rheumatol 2004, 31:5-7.
91. Solomon D.H., Rassen J.A., Glynn R.J., Lee J., Levin R., Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010, 170:1968-1976.
92. Arendt-Nielsen L., Nie H., Laursen M.B., Laursen B.S., Madeleine P., Simonsen O.H., et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010, 149:573-581.
93. Hochberg M.C., Wohlreich M., Gaynor P., Hanna S., Risser R. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012, 39:352-358.
94. Risser R.C., Hochberg M.C., Gaynor P.J., D'Souza D.N., Frakes E.P. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage 2013, 21:691-694.
95. Neogi T., Frey-Law L., Scholz J., Niu J., Arendt-Nielsen L., Woolf C., et al. Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state?. Ann Rheum Dis 2013, [Epub ahead of print].
96. Ethgen O., Bruyere O., Richy F., Dardennes C., Reginster J.-Y. Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 2004, 86-A:963-974.
97. Griffin T., Rowden N., Morgan D., Atkinson R., Woodruff P., Maddern G. Unicompartmental knee arthroplasty for the treatment of unicompartmental osteoarthritis: a systematic study. ANZ J Surg 2007, 77:214-221.
98. Brouwer R.W., Raaij van T.M., Bierma-Zeinstra S.M., Verhagen A.P., Jakma T.S., Verhaar J.A. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev 2007, CD004019.
99. Laupattarakasem W., Laopaiboon M., Laupattarakasem P., Sumananont C. Arthroscopic debridement for knee osteoarthritis. Cochrane Database Syst Rev 2008, CD005118.
100. Nüesch E., Rutjes A.W., Husni E., Welch V., Jüni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009, 7:CD003115.
101. Chou R., Fanciullo G.J., Fine P.G., Adler J.A., Ballantyne J.C., Davies P., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
102. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.